MK0457 in Patients With Leukemia (0457-003)

Phase 1 Completed 28 enrolled Merck Sharp & Dohme LLC

NaSingle-groupOpen-labelTreatment

Summary

In this study participants with relapsed/refractory leukemia will be given MK-0457 in sequential cohorts and with varying treatment duration to determine the maximum tolerated dose (MTD) for MK-0457.

Timeline

Start: 2005-06
Primary completion: 2008-05
Completion: 2008-05

Publications

Results Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia. 2013 Jan;27(1):113-7. doi: 10.1038/leu.2012.186. Epub 2012 Jul 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TOZASERTIB	Small molecule	40 mg/m2	Intravenous
Subject	TOZASERTIB	Small molecule	144 mg/m2	Intravenous

MK0457 in Patients With Leukemia (0457-003)

Summary

Timeline

Publications

Drugs

Indications